LATEST NEWS

16/09/2018

ACTERO WELCOMED LEBANESE REPORTERS TO ITS MANUFACTURING FACILITIES

On 9th September, a media team consisting of 30 reporters from Lebanon came to visit Actero. During this visit, they interviewed Actero specialists and witnessed in person the safety and quality of production lines of Actero.

“We, at Actero, are committed to quality and our manufacturing facility is operating under strict GMP criteria to produce solid and injectable dosages.”

Dr. Norouzpour – Head of Engineering

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

10/09/2018

AUTHORITIES OF PROVINCIAL GOVERNMENT VISITED ACTERO MANUFACTURING FACILITY

On 4th September authorities of Alborz province government visited the Actero facility. Mr. Najafi, Deputy Minister of Industry, Mr. Shahmoradi, Chairman of Alborz Industry Organization and other officials honored Actero with their presence and visited the facility and its potentials. Earlier this year, the regional government had recognized Actero as an outstanding project.

“Actero is the biggest manufacturer of oncology products in the Middle East and aims to be actively present in both national and international markets.”

Dr. Ravindra Babu, Plant Head

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

01/09/2018

IN A COLLABORATION WITH MAHAK, ACTERO MEMBERS TOOK PART IN A STEM CELL DONATION PROGRAM

Members of Actero family took part in a stem cell donation program by giving a sample of their salvia. The program was executed on 14th August at the company head office by Mahak charity and samples were gathered for submission to Human Leukocyte Antigen bank.

“As a company active in manufacturing oncology products we are well aware of the hardship of cancer treatment; that is why we feel responsible to partake in such programs.”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.
Mahak, the society to support children from cancer, has provided comprehensive coverage and treatment to over 27000 children and their families.

If you would like more information about this topic, please contact us at news@acteropharma.com

06/08/2018

ACTERO WELCOMED DISTINGUISHED ONCOLOGISTS FOR A SITE VISIT

On 2nd August, renowned oncologists of Iran visited Actero manufacturing facility located in Alborz province. In this ceremony, distinguished oncologists visited the production line of Acteo and were introduced to current and future Actero products.

“It is our great honor to welcome distinguished oncologists to our manufacturing facility and let them witness our potential and commitment to manufacture high-quality oncology products.”

Dr. Tiam Esfahani, Sales and Marketing Director

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

15/07/2018

ACTERO RECEIVES PRIZE ON THE NATIONAL DAY OF INDUSTRIES AND MINES

Actero received a prize from the regional government of the Province of Alborz where the plant is situated. The Province of Alborz and the Ministry of Industry and Mines awarded eminent entrepreneurs in different sectors and recognized the importance of the industrial infrastructure in Iran.

“In Actero we are committed to local manufacturing and our international partners will continue investing resources to produce high-quality products through technology transfer”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

11/07/2018

DR. ASGHARI THE DEPUTY MINISTER OF HEALTH AND CHAIRMAN OF IRANIAN FDA VISITED ACTERO MANUFACTURING PLANT

Dr. Asghari, deputy minister, Dr. Borandegi, director of pharmaceutical products in the FDA and Dr. Sheibani Chairman of Iranian Pharma syndicate among other officials honored Actero with their presence and could witness firsthand the progress of the plant.

“It is a pleasure to welcome our guests in Actero for this progress review. In less than one month, the Solid Dosage Form manufacturing line will start production and oncology products like Capecitabine ACTe will be produced locally”

Dr. Ravindra Babu, Plant Head

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

15/04/2018

ACTERO LAUNCHES DOXORUBICIN ACTE AND ETOPOSIDE ACTE

Actero Middle East is pleased to announce the launch of two new molecules to the Iranian market. Doxorubicin ACTe 10mg and 50mg and Etoposide ACTe 100mg/5ml. Doxorubicin ACTe 10mg and 50mg injections are the generic version of Adriamycin, a chemotherapy medication used to treat a broad range of cancers including breast cancer, bladder cancer, Kaposi’s sarcoma, lymphoma, and acute lymphocytic leukemia. Etoposide ACTe 100mg/5ml injections are the generic version of Etopophos, a chemotherapy medication used to treat a broad range of cancers including testicular cancer, lung cancer, lymphoma, leukemia, neuroblastoma, and ovarian cancer.

“Doxorubicin ACTe and Etoposide ACTe are the two latest products in our growing oncology portfolio. With these new additions, we aim to gain the trust of all stakeholders and continue building a portfolio where every Actero medicine stands for reliability.”

Shahrzad Gonzalez-Quijano, CEO of Actero

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com

20/12/2017

ACTERO LAUNCHES CAPECITABINE ACTE 500MG

Actero Middle East is pleased to announce the launch of its first product to the Iranian market. This launch is a milestone for our young company but it is only the first step towards building our oncology portfolio. Capecitabine ACTe 500mg tablets are equivalent to Xeloda tablets, a chemotherapy medication used to treat breast cancer, gastric cancer and colorectal cancer.

“The approval and launch of Capecitabine ACTe is a good news for oncologists and patients that will have access to a wider range of quality products to choose from. We aim to make our products available in the market and hope to create more competition based solely on quality and let doctors make their choice.”

Dr. Tiam Esfahani, Sales and Marketing Director

Actero is a pharmaceutical company specialized in high-quality oncology products and has over 15 products under development or pending Ministry of Health approval.

If you would like more information about this topic, please contact us at news@acteropharma.com